Maze Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Coloma
- Full Time Employees
- 141
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 171 Oyster Point Blvd South San Francisco CA United States of America 94080
- IPO Date
- Jan 31, 2025
- CIK
- 0001842295
- Website
- mazetx.com
- Similar Companies
- Business
- Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company that harnesses human genetics through its proprietary Compass platform to develop novel small molecule precision medicines for patients with renal, cardiovascular, and related metabolic diseases, including obesity and chronic kidney disease (CKD); the platform identifies and characterizes genetic variants in diseases, links them to underlying biological pathways via variant functionalization, and informs drug discovery, development, and clinical trial design across all phases. Founded in 2018 and headquartered at 171 Oyster Point Blvd., Suite 300, South San Francisco, California, the company advances a pipeline led by two wholly owned programs targeting CKD, which affects approximately 37 million people in the United States: MZE829, an oral small molecule APOL1 inhibitor for APOL1-mediated kidney disease (AKD) estimated to impact over one million individuals, particularly those with focal segmental glomerulosclerosis (FSGS), following positive Phase 1 results in October 2024 showing good tolerability, dose-proportional pharmacokinetics, and no serious adverse events, with a Phase 2 trial initiated in November 2024 and first patient dosing expected in the first quarter of 2025 and proof-of-concept data in the first quarter of 2026; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19 for CKD patients inadequately responding to standard therapies, with potential standalone or combination use and applicability to phenylketonuria (PKU), following Phase 1 trial initiation in September 2024 and initial data expected in the second half of 2025, alongside plans for a parallel Phase 2 trial in PKU. The company operates primarily in the United States, focusing on genetically defined patient subsets within common diseases through its end-to-end research tools and methodologies that prioritize protective genetic effects to mimic natural disease modification. Recent developments include an oversubscribed $115 million Series D financing in December 2024 co-led by Frazier Life Sciences and Deep Track Capital with participation from Janus Henderson Investors, Logos Capital, and existing investors including Foresite Capital, to advance MZE829 and MZE782 clinical programs and expand platform capabilities following conversion of prior convertible notes; an initial public offering (IPO) on Nasdaq priced at $16 per share in January 2025 raising approximately $140 million; positive Phase 1 readout for MZE829 and ongoing enrollment in its Phase 2 trial; and Phase 1 initiation for MZE782, positioning Maze to disrupt CKD treatment paradigms beyond current disease management approaches.
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
Maze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference